Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New Feature:   All Finviz Members Now Get Real-Time Earnings Data

Read More
Market News Market Pulse Stocks News ETF News Crypto News

Allarity Therapeutics, Inc.

Contributing Author

Recent Articles by Allarity Therapeutics, Inc.

Sep-30
Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor to Drive Stenoparib's Clinical Development ALLR +8.80% GlobeNewswire
Sep-28
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research ALLR -5.98% GlobeNewswire
Sep-15
Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP Companion Diagnostic, Further Strengthening Stenoparib Development ALLR -5.13% GlobeNewswire
Sep-11
Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement ALLR GlobeNewswire
Aug-14
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign ALLR GlobeNewswire
Jul-07
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP Testing for FDA Registration ALLR -5.83% GlobeNewswire
Jun-30
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP Companion Diagnostic ALLR GlobeNewswire
Jun-18
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026 ALLR +6.72% GlobeNewswire
May-15
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers ALLR -10.60% ALLR +5.93% GlobeNewswire
May-08
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm ALLR GlobeNewswire
May-05
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign ALLR +12.00% GlobeNewswire
Apr-27
Allarity Therapeutics Announces that the Stenoparib DRP Test Has Received a Notice of Allowance from the US Patent and Trademark Office ALLR GlobeNewswire
Apr-21
Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib's Potential in Colorectal Cancer as well as New Predictive Data Linking DRP and Overall Survival in Ovarian Cancer ALLR +10.40% GlobeNewswire
Mar-31
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress ALLR GlobeNewswire
Mar-06
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization ALLR +21.57% GlobeNewswire
Feb-18
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need ALLR +8.67% GlobeNewswire
Feb-03
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment ALLR -8.06% GlobeNewswire
Dec-31
Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders ALLR +6.93% GlobeNewswire
Nov-14
Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates ALLR GlobeNewswire
Sep-22
Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months ALLR +15.58% GlobeNewswire
Sep-17
Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025 ALLR GlobeNewswire
Aug-26
Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer ALLR +51.92% GlobeNewswire
Aug-15
Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships ALLR ALLR -5.00% GlobeNewswire
Jul-15
Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP Platform Utilization ALLR GlobeNewswire
Jul-07
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer ALLR GlobeNewswire
Jun-30
Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP Companion Diagnostic ALLR GlobeNewswire
Jun-27
Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer ALLR GlobeNewswire
Jun-11
Allarity Therapeutics Announces Changes to Board of Directors ALLR ALLR -5.31% GlobeNewswire
Jun-04
Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib's Unique, Dual Therapeutic Mechanism of Action ALLR GlobeNewswire
Jun-02
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer ALLR GlobeNewswire
May-12
Allarity Therapeutics Announces Participation in Pharma Partnering Summit US ALLR GlobeNewswire
May-09
Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment ALLR GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)